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Current recommendations for diagnosing myelodysplastic syn-dromes endorse flow cytometry as an informative tool. Most flowcytometry protocols focus on the analysis of progenitor cells and the
evaluation of the maturing myelomonocytic lineage. However, one of the
most frequently observed features of myelodysplastic syndromes is ane-
mia, which may be associated with dyserythropoiesis. Therefore, analysis
of changes in flow cytometry features of nucleated erythroid cells may
complement current flow cytometry tools. The multicenter study within
the IMDSFlow Working Group, reported herein, focused on defining flow
cytometry parameters that enable discrimination of dyserythropoiesis asso-
ciated with myelodysplastic syndromes from non-clonal cytopenias. Data
from a learning cohort were compared between myelodysplasia and con-
trols, and results were validated in a separate cohort. The learning cohort
comprised 245 myelodysplasia cases, 290 pathological, and 142 normal
controls; the validation cohort comprised 129 myelodysplasia cases, 153
pathological, and 49 normal controls. Multivariate logistic regression analy-
sis performed in the learning cohort revealed that analysis of expression of
CD36 and CD71 (expressed as coefficient of variation), in combination
with CD71 fluorescence intensity and the percentage of CD117+ erythroid
progenitors provided the best discrimination between myelodysplastic syn-
dromes and non-clonal cytopenias (specificity 90%; 95% confidence inter-
val: 84–94%). The high specificity of this marker set was confirmed in the
validation cohort (92%; 95% confidence interval: 86–97%). This erythroid
flow cytometry marker combination may improve the evaluation of
cytopenic cases with suspected myelodysplasia, particularly when com-
bined with flow cytometry assessment of the myelomonocytic lineage.  
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ABSTRACT
Introduction
Discriminating between cytopenia due to myelodys-
plastic syndromes (MDS) and cytopenia due to other
(non-clonal) causes can be challenging, especially when
dysplasia as assessed by cytomorphology does not fulfill
the diagnostic criteria of MDS according to WHO1, and
when other MDS-associated features are absent (e.g.,
>15% ring sideroblasts (RS) and/or cytogenetic aberra-
tions). Current recommendations for the diagnosis of
MDS endorse flow cytometry (FC) as a valuable addition-
al diagnostic tool. In this respect, it has been recommend-
ed to follow the guidelines set down by the
International/European LeukemiaNet Working Group for
FC in MDS (IMDSFlow).2-4
Despite the fact that FC for MDS correlates with cyto-
morphology, the sensitivity of current validated FC scores
for diagnosing MDS requires improvement.5-8 So far, most
of the designed FC scores have comprised the analysis of
the (im)mature myelomonocytic lineage with a median
sensitivity of 75% for identifying MDS (median specifici-
ty, 94%; see Westers et al.4). Since anemia is frequently
observed in MDS, often accompanied by erythroid dys-
plasia, analysis of immunophenotypic changes of nucleat-
ed erythroid cells (NEC) may complement current FC
analysis.9,10 Thus far, this has not been studied in great
detail. Integration of results from analysis of the erythroid
lineage to the primarily myelomonocytic and progenitor
cell-based FC scores may improve sensitivity of FC analy-
sis in MDS.8;11-13
Incorporating erythroid markers in FC protocols
requires knowledge of normal erythroid differentiation,
and of potential aberrancies and pitfalls. The characteris-
tic morphological stages of normal erythroid differentia-
tion are reflected by their light scatter properties and by
their differential expression of CD45, CD117, CD105,
CD36, CD71 and/or CD235a (Figure 1).14-17 Some of the
FC aberrancies that have been reported to reflect MDS-
related dyserythropoiesis are: a) an increased number of
NEC within total nucleated cells; b) an altered proportion
of consecutive erythroid differentiation stages, such as an
increased number of immature erythroid cells (CD117+
and/or CD105+) or, by contrast, a decrease in erythroid
progenitors; c) an abnormal pattern of CD71 versus
CD235a; d) a reduced expression of CD71 and/or CD36;
and e) an overexpression of CD105. Most of these aber-
rancies are present in 70–80% of MDS cases.8,11-13,15,18-22
However, a number of features may be shared across the
spectrum of non-clonal cytopenias.23-25
The multicenter study reported herein focused on
defining the erythroid FC parameters that enable distinc-
tion of dyserythropoiesis associated with MDS from non-
clonal cytopenias. Hereto, data from a learning cohort
were compared between MDS patients and controls, and
the results were validated in a separate cohort. 
Methods
MDS patients and controls
Nineteen centers (members of the IMDSFlow group) collected
FC data on the erythroid lineage in low grade MDS cases (<5%
blasts) and controls. Data were acquired from bone marrow
samples taken from 1008 patients and healthy controls after
informed consent in accordance with the Declaration of
Helsinki; where required, local ethics committee approval was
obtained. The learning cohort comprised 677 cases (18 centers,
data collected between October 2012 and September 2013), and
the validation cohort comprised 331 cases (9 centers, data col-
lected between December 2013 and April 2014). Inclusion crite-
rion for pathological controls was cytopenia not associated with
MDS. In total, data on 374 MDS cases, 443 pathological and 191
normal controls were collected (specified in Tables 1 and 2).
Information regarding age, gender, cytomorphology and cytoge-
netics was requested. One center with limited access to cyto-
morphology results only included MDS patients with typical
features of MDS as the presence of more than 15% RS and/or
MDS-associated cytogenetic anomalies. In 325/374 MDS cases,
sub-classification according to the WHO-20081 was provided.
The median contribution per center to the total study cohort
was 47 cases (range 6–100); the median number of erythroid FC
markers analyzed per case was 7 (range 1–9 of 10 proposed
markers).
Sample preparation and antibody combinations
Flow cytometric analysis in MDS requires the removal of
mature, enucleated erythrocytes through the use of lysis proto-
cols. The vast majority of centers used ammonium chloride-
based solutions, either home-made or commercial (e.g.,
PharmLyse; BD Biosciences, San Jose, CA); two centers used
FACSLyse (BD Biosciences), and one other used VersaLyse
(Beckman Coulter, Miami, FL). FACSLyse contains a fixative,
whereas VersaLyse is recommended for use with a fixative when
the sample contains anticoagulants other than EDTA. The dura-
tion of lysis and temperature varied among centers (5–25 min-
utes and 4–37°C, respectively), but most lysed for 10 minutes
(n=10) at room temperature (n=16). Two centers reported the
use of an additional fixative in their staining protocols, both in
combination with an ammonium chloride-based lysing solution.
Detailed information can be found in Online Supplementary
Information. Most centers used the IMDSFlow-recommended
stain-lyse-wash procedure; five centers performed stain-lyse-
wash. Antibody combinations were similar between centers,
but clones and fluorochromes differed. Most centers used a
backbone of CD45 and CD34 and/or CD117, and added anti-
bodies such as CD235a, CD71, CD36, and CD105. Examples of
antibody combinations and panels have been described previ-
ously.3,26,27 Nuclear dyes were not routinely included in the pan-
els, and only one center applied the live/dead stain 7-AAD. The
flow cytometers used included: FACSCalibur (BD Biosciences;
n=3); FACS CANTO-II (BD Biosciences; n=10); a combination of
FACSCalibur and FACS CANTO-II (both BD Biosciences; n=2);
and Navios (Beckman Coulter; n=4).  Panels comprised 4-, 5-, 6-
, 8- and/or 10-color FC; WinList7.0 (Verity Software House,
Topsham, ME), Kaluza (Beckman Coulter), CellQuestPro, FACS-
DIVA (both BD Biosciences), and/or Infinicyt (Cytognos,
Salamanca, Spain) software packages were used for data analy-
sis.
Gating strategy and data collection
The gating strategy was discussed during the IMDSFlow
meeting in 2011 and re-evaluated in 2012. All participants per-
formed FC analysis of the erythroid lineage defined as CD45dim-
to-negative and SSClow-to-intermediate. It is noteworthy that the initially
proposed gating strategy (erythroid lineage defined by CD45
negativity) was altered to include early erythroid precursors that
are within the CD45dim cell population.3,4,13 Six or more color
panels enabled the inclusion of a myeloid-defining marker such
as CD13 or CD33, and a more accurate separation of myeloid
and erythroid progenitors. Moreover, to exclude platelets and
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platelet aggregates, a combination of scatter properties and
CD36high/CD71- was suggested. The final gating strategy was
distributed among all centers (detailed information in Online
Supplementary Information).
The following parameters were collected: the percentage of
NEC within all nucleated cells; the expression pattern of CD71
versus CD235a; the percentage of CD71dimCD235a+ cells within
the CD71/CD235a pattern; CD71 and CD36 expression levels;
the percentage of CD117+ cells in the erythroid compartment;
CD105 expression level and the percentage of CD105+ cells in
the erythroid compartment. Recent knowledge, such as the find-
ing that CD71 and CD36 expression represented as CV is statis-
tically more significant than when represented as mean fluores-
cence intensity (MFI)28, led to adjustments in the initially pro-
posed protocol and, hence, reanalysis of the list mode data files
by the individual centers. Gating strategies and analyzed param-
eters are shown in the Online Supplementary Information with FC
plots of MDS in comparison to normal subjects.
Statistical analyses
Due to differences in sample processing, instrument settings,
clones, and fluorochromes between centers, the expression lev-
els of CD71, CD36, and CD105 varied. Therefore, the median
expression levels of CD36, CD71, and CD105 in the subset of
normal bone marrow samples were calculated for each individ-
ual center. Expression levels were then normalized against the
median value for that particular marker for each center separate-
ly. Patient and control groups were compared using the Kruskal
Wallis test for continuous data, and the Chi-square or the
Fisher’s exact test for dichotomous data. Correlations between
certain markers, and between markers and age, were analyzed
using Spearman’s rank correlation coefficients. Comparing single
parameters between MDS and control groups demonstrated that
results overlapped (results section figure 2); hence, receiver-oper-
ator-curve (ROC) analyses did not yield applicable cut-offs.
Therefore, cut-off values for aberrancies were based on the 10th
and/or 90th percentile of the data of pathological controls in the
learning cohort. Multivariate logistic regression analyses were
performed to determine the erythroid markers that discriminate
between pathological controls and MDS; data were analyzed
dichotomously. All variables that displayed a univariate differ-
ence of P<0.1 were included in a backward selection procedure
based on the Likelihood Ratio score. Regression coefficients of
the variables in the final model were used to define the weight
of these markers in a descriptive score for dyserythropoiesis.
Cut-off level of the score indicating MDS-associated erythroid
aberrancies was determined based on the total weight of these
variables and a specificity of at least 90%. The sensitivity and
specificity of the marker combination were calculated to illus-
trate predictive accuracy. The data were analyzed using SPSS
20.0 (IBM Corp, Armonk, NY), and GraphPad 6.0 software (La
Jolla, CA). P-values <0.05 were considered significant.
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Table 1. Characteristics of MDS patients and controls in the learning
and validation cohorts.
                                                  Learning cohort       Validation cohort
Normal                                                                                                        
n                                                                        142                                   49
age                                                             60 (20-86)*                     64 (24-86)*
male:female                                                  1.4:1                                2.3:1
Pathological controls                                                                               
n                                                                        290                                  153
age                                                           62 (18-92)*                   72 (20-98)*
male:female                                                    1:1                                  1.2:1
MDS                                                                                                             
n                                                                        245                                  129
age                                                           72 (23-94)*                   75 (40-95)*
male:female                                                  1.1:1                                1.6:1
Comparison of age                                                                                   
normal vs. pathological controls         P = 0.007                       P = 0.193
pathological controls vs. MDS              P < 0.001                       P = 0.013
Comparison of gender                                n.s.                                  n.s.
*Data are expressed as the median and range; abbreviations: MDS: myelodysplastic
syndromes; n: number; n.s.: not significant.
Table 2. Subcategories of MDS and pathological controls in the learn-
ing and validation cohort.
                                                                         Learning          Validation
                                                                          cohort               cohort
MDS subcategories                                                                                            
RCUD                                                                           23 (9.4%)              14 (11%)
RARS                                                                            16 (6.5%)             12 (9.3%)
RARS-t                                                                           2 (0.8%)               1 (0.8%)
RCMD                                                                          155 (63%)             75 (58%)
del(5q)                                                                        14 (5.7%)              5 (3.9%)
MDS-U                                                                          3 (1.2%)               3 (2.3%)
other                                                                                                           2 (1.6%)*
not specified                                                              32 (13%)            17 (13%)**
Subcategories of pathological controls                                                        
iron deficiency anemia                                            22 (7.6%)             13 (8.5%)
anemia in chronic disease†                                   42 (14.5%)             8 (5.2%)
vitamin B12/folic acid deficiencies                       11 (3.8%)             11 (7.2%)
anemia in auto-immune diseases†                       13 (4.5%)              7 (4.6%)
anemia due to renal failure                                     6 (2.1%)               5 (3.3%)
anemia other                                                               9 (3.1%)               9 (5.9%)
cytopenia associated with                                      20 (6.9%)              7 (4.6%)
marrow infiltration                                                                                           
cytopenia induced by chemotherapy                   27 (9.3%)              8 (5.2%)
or medication or post-SCT                                              
ITP or neutropenia or
auto immune cytopenia NOS                                30 (10.3%)            14 (9.2%)
reactive conditions or
cytopenia induced by infections                            32 (11%)              10 (6.5%)
normal bone marrow, peripheral cytopenia        6 (2.1%)                      0
other than defined subcategories                        29 (10%)              23 (15%)
inconclusive                                                               11 (3.8%)              8 (5.2%)
non clonal cytopenia NOS                                      25 (8.6%)            19 (12,4%)
ET, PV, primary myelofibrosis                                  5 (1.7%)               7 (4.6%)
PNH                                                                               1 (0.3%)                      0
AA                                                                                   1 (0.3%)               4 (2.6%)
Values between brackets represent the relative distribution within MDS or pathologi-
cal control subgroups; *other concerns one case of hypoplastic MDS and one case of
MDS with fibrosis; **not specified, but the presence of MDS-associated cytogenetic
aberrations indicated; AA: aplastic anemia, ET: essential thrombocythemia; MDS:
myelodysplastic syndromes, MDS-U: MDS-unclassifiable; NOS: not otherwise specified,
PNH: paroxysmal nocturnal hemoglobinuria, PV: polycythemia vera; RARS: refractory
anemia with ring sideroblasts; RARS-t: RARS and thrombocytosis; RCMD: refractory
cytopenia with multilineage dysplasia, RCUD: refractory cytopenia with unilineage
dysplasia,  del(5q): MDS with isolated del(5q). Comparison of the distribution of MDS
subsets among the learning and validation cohorts did not differ (c2 test; P=0.511); the
distribution of subsets of pathological controls did (P<0.001). The subcategories† ”ane-
mia in chronic disease” comprises iron incorporation disorders, bowel diseases, dia-
betes, etc., “anemia in auto-immune diseases” comprises AIHA, AITP, Rheumatoid
Arthritis, SLE, etc.; “anemia other” comprises, among others, cases of normocytic ane-
mia, anemia unexplained.
Results
Flow cytometric analysis of the erythroid lineage in
normal bone marrow samples: comparison of results
from participating centers
Discrepancies in erythroid analysis between centers (and
samples) can occur at several levels: a) sample quality (e.g.,
hemodilution); b) sample preparation (e.g., lysing proce-
dure); c) data acquisition (e.g., acquisition rate and threshold
of forward light scatter); and d) degree of adherence to the
proposed gating strategy. Therefore, we first compared the
FC results for normal bone marrow samples (learning
cohort) between centers in terms of each defined marker.
The percentage of NEC was highly diverse among centers;
yet, it seemed to be independent of the lysing method
applied (Online Supplementary Figure S1). Similarly, the per-
centage of CD71dim cells differed largely between centers.
Furthermore, two centers reported higher percentages of
CD117+ erythroid progenitors (up to 50% within the NEC)
than the other centers (<15%). Results for one center could
be explained by their stringent lysing procedures (i.e., 15
minutes at 37°C) which removed more mature (orthochro-
matic and polychromatic) erythroblasts resulting in a rela-
tive increase in early progenitors (data not shown). To circum-
vent the issues regarding differences in percentages of ery-
throid (sub)populations between centers, the percentages of
NEC, CD117+ and CD105+ erythroid progenitors were also
normalized as described for antigen expression levels (see
Material and Methods statistics section); these are further
referred to as relative percentages, i.e., relative to the medi-
an percentage in normal bone marrow samples (Online
Supplementary Figure S2). CD71dim cells were rarely seen in
normal controls; therefore, results for the percentage
CD71dim could not be normalized. 
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Figure 1. Flow cytometric profiles of normal erythroid differentiation. Early erythroid precursors are defined as CD45dim/SSCint/CD34+/CD117+/CD105+/CD235a-,
proerythroblasts as CD45dim/–/SSCint/CD34–/CD117+/CD105+/CD36+/CD71+/CD235a+, basophilic erythroblasts as CD45dim/–/
SSCint/CD117–/CD105+/CD36++/CD71+/CD235a+, polychromatic erythroblasts as CD45–/SSClow/FSCint/CD105–/CD36+/CD71+/CD235a+ and orthochromatic erythrob-
lasts CD45–/ SSClow/FSClow/CD36+/-/CD71+/CD235a+. Indicated colors reflecting erythroid subsets are not visible in the CD71 vs. CD235a plot (Fig 1F). Herein, pink
colored cells represent the total erythroid lineage in this plot. Mature erythrocytes (CD45–/CD36–/CD71–/CD235a++) can be seen in improperly lysed cell preparations
(Figure 1F). Reticulocytes are not covered in these graphs, but they may appear as CD71dim-to-negative in non-lysed cell preparations. Myeloid progenitors are
CD34+/CD117+/HLA-DR+/CD105– (Figure 1C and D.); these cells have slightly higher CD45 expression than erythroid precursors; moreover, in contrast to myeloid
progenitors erythroid cells do not express HLA-DR (adapted from references 14-16).
A B
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Erythroid aberrancies that may discriminate between
MDS and pathological controls
Next, all FC-erythroid parameters in the learning cohort
were compared between MDS and controls. The results
from the learning cohort are summarized in Figure 2 
(P-values in Online Supplementary Table S1). The relative per-
centage of NEC within the total nucleated cell population
was significantly higher in MDS than in the pathological
and normal controls (P<0.001). Similarly, the CD71-
CD235a differentiation pattern was more frequently con-
sidered aberrant in MDS (65%, 109/167 cases) than in
pathological and normal controls (18% (44/254) and 3.7%
(5/134) of cases, respectively (P<0.001)). To objectify the
evaluation of this pattern, we analyzed its components sep-
arately. CD71 expression was analyzed in terms of MFI,
CV, and the presence of a subpopulation with reduced
CD71 expression (CD71dim). The relative CD71 MFI was
significantly reduced in MDS, whereas the relative CV for
CD71 and the percentage of CD71dim cells were significantly
higher than those in both control groups (P<0.001); no sig-
nificant differences were observed between the pathologi-
cal controls and normal bone marrow samples. The expres-
sion of CD235a largely depends on the success of removing
mature erythrocytes from a sample. Moreover, membrane
fragments of lysed erythrocytes may stick to other cells in
the analysis sample, mimicking positivity. Hence, this
parameter was considered too unreliable for evaluation
when considered individually. 
The percentage of immature erythroid progenitors can
also affect the appearance of the differentiation pattern.
Analysis of the relative percentage of CD117+ (and
CD105+) erythroid progenitor cells revealed a broader
T.M. Westers et al.
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Figure 2. Distribution of erythroid markers analyzed by flow cytometry among MDS patients and controls within the learning cohort. Results of the analysis of indi-
cated markers of the erythroid lineage are plotted along the X-axes: relative (rel.) percentages of nucleated erythroid cells (NEC); rel. mean fluorescence intensity
(MFI) for CD36, CD71, and CD105; rel. coefficient of variation (CV) of CD36 and CD71; and rel. percentages of CD117+ and CD105+ erythroid progenitors. Relative
frequencies (as percentage of the MDS or control cohort for a particular marker) are depicted along the Y-axes. Dotted lines represent results for normal bone marrow
(NBM) samples, dashed lines pathological controls (PC) and solid lines MDS cases. P-values of comparison between groups are depicted: **: <0.001, *: <0.05, ns:
not significant (Kruskal Wallis test). Grey boxes indicate reference ranges for the analyzed markers as defined by 10th and 90th percentiles of pathological controls.
Scatterplots of results for the markers (depicted here as frequency histograms) that were selected as FC-markers for erythroid dysplasia from the multivariate analysis
are depicted in Online Supplementary Figure S3. 
range of these cells in MDS, although not significantly dif-
ferent from the control groups. 
Relative expression of CD105 was either increased or
decreased in MDS. Nonetheless, CD105 expression did
not discriminate between MDS and pathological controls. 
Similar to that for CD71, the relative MFI of CD36 was
significantly lower and the relative CV for CD36 was sig-
nificantly higher in MDS than in the control groups. 
To summarize, the markers that showed a significantly
different distribution in MDS as compared to controls
were: the relative percentage of NEC and the percentage
of CD71dim cells (increased in MDS); the relative MFI of
CD71 and CD36 (decreased in MDS); and the relative CV
for CD71 and CD36 (increased in MDS); Figure 2. 
Selection of a combination of erythroid FC aberrancies
that distinguish MDS from pathological controls
To be applicable in FC analysis of a single patient in
daily practice, cut-offs for the identification of MDS-asso-
ciated changes of all potential aberrancies were defined
(10th and 90th percentiles of the pathological controls,
Online Supplementary Table S2A) and compared between
MDS and controls (Table 3). All parameters differed
between groups at a P-value of <0.1, and thus could have
been considered for the multivariate logistic regression
analysis. However, due to large differences between cen-
ters, regarding the percentages of NEC and CD71dim cells
(likely due to technical variation as shown for normal con-
trols), these parameters were not entered in the multivari-
ate analysis. Besides, irrespective of the finding that data
for CD105 significantly discriminated between subgroups
(Table 3), this marker was not included. Entering CD105
data would have reduced the power of the (multicenter)
analysis, since data on CD105 were only available in a lim-
ited number of centers (5/18) and cases. Multivariate logis-
tic regression analysis was based on 119 MDS cases and
153 pathological controls that had available data for all
parameters entered in the test. CD36 CV was identified as
the best discriminator between MDS and pathological
controls in combination with the CV of CD71, the MFI of
CD71 and the percentage of CD117+ erythroid cells (Table
4). These four markers were used to define a FC-erythroid
dysplasia score in which aberrancies were considered in a
weighted manner: four points for increase in CD36 CV;
three points for increase in CD71 CV; two points for
decreased CD71 MFI; and two points in the case of
decreased or increased percentage of CD117+ erythroid
cells (reference ranges are summarized in Table 5). A cut-
off of ≥5 points resulted in the identification of MDS-asso-
ciated erythroid aberrancies by FC at a specificity of 90%
(95% CI: 84–94%) and a sensitivity of 33% (95% CI: 24–
42). Results for the selected markers and the application of
the FC-erythroid dysplasia score in the learning cohort are
displayed in Table 6 and Figure 3A. In daily practice, a
numerical way of counting aberrancies would be more
convenient. This involves the definition of a new cut-off;
i.e., ≥2 aberrant markers (Figure 3C). Note that, the excep-
tion to this numerical score is that the combination of
aberrancies in CD71 MFI and percentage of CD117+ alone
is not sufficient to conclude dyserythropoiesis by FC (<5
points in the weighted score). The latter was seen in only
one pathological control and three MDS cases. 
Correlation between erythroid markers and age
The incidence of MDS increases with age; hence, ery-
throid markers that are significantly correlated with age
may be less suitable for discriminating between MDS and
controls. Since we observed significant differences
between the groups regarding age (Table 1); correlations
between FC results for erythroid markers and age were
evaluated for normal bone marrow samples. Only CD105
MFI, a variable that was not included in the multivariate
analysis, demonstrated a moderate-to-good inverse corre-
lation with age, i.e., CD105 expression decreased with
increasing age (Spearman’s Rho -0.55, P<0.001, n=47,
Online Supplementary Table S4 and Online Supplementary
Figure S4). 
Validation of FC aberrancies in the erythroid lineage 
in MDS and pathological controls
The value of the defined antigenic combinations was
tested in an independent cohort. Nine centers provided
Flow cytometric analysis of erythrodysplasia in MDS
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Table 3. Aberrancies in FC markers of the erythroid lineage between MDS and controls within the learning cohort.
NBM PC MDS P P P
MDS MDS PC 
vs. PC vs. NBM vs. NBM
rel. %NEC 2.9 10.1 32.1 <0.001 <0.001 0.013
pattern CD71 vs. CD235a 3.7 17.3 64.9 <0.001 <0.001 <0.001
%CD71dim 0.8 10.0 31.5 <0.001 <0.001 <0.001
rel. MFI of CD71 4.0 10.0 27.8 <0.001 <0.001 0.045
rel.CV of CD71 4.5 10.3 45.5 <0.001 <0.001 0.152
rel. MFI of CD36 0.8 10.3 25.8 0.001 <0.001 <0.001
rel. CV of CD36 0.0 10.2 30.1 <0.001 <0.001 0.001
rel. %CD117 progenitors 8.2 19.4 33.8 0.005 <0.001 0.008
rel. %CD105 progenitors 6.7 20.8 48.4 0.001 <0.001 0.092
rel. MFI of CD105 29.8 22.5 58.7 <0.001 0.004 0.395
After applying cut-offs as defined in the set of pathological controls, the results were expressed as ‘0’ and ‘1’ for within and beyond reference range(s), respectively (ranges as dis-
played in Online Supplementary Table S2A). Percentages of subjects with aberrancy are displayed for normal bone marrow (NBM), pathological controls (PC) and MDS cases.
Results were compared among subgroups using Fisher’s Exact test; P-values are depicted (P).  CV: coefficient of variation; dim: diminished; MFI: mean fluorescence intensity;
NEC: nucleated erythroid cells; P: P-value; rel.: relative.
data for this validation cohort, the results are depicted in
Figure 4 and Online Supplementary Table S1. Similar to
results in the learning cohort, the relative CVs of CD36
and CD71 were significantly increased in MDS as com-
pared to controls, whereas CD36 MFI was significantly
decreased. Since the distribution of subcategories was
similar in the MDS learning and validation cohorts, we
compared FC results between the two MDS cohorts. This
revealed that the increase in CD71 CV and the decrease in
CD71 MFI were significantly less evident in the MDS val-
idation cohort than in the learning cohort (t-test, P<0.001).
Results for CD36 CV and the percentage of CD117+ ery-
throid cells did not differ between both MDS cohorts
(P=0.134 and 0.116, respectively). 
Reference ranges, as defined in the learning cohort, were
applied to evaluate the data from the validation cohort,
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Figure 3. FC-erythroid dysplasia score in learning
and validation cohorts. The weighted score consists
of four parameters: increase in CD36 CV (4 points)
and CD71 CV (3 points); decrease in CD71 MFI (2
points); and decrease or increase of CD117+ ery-
throid progenitors (2 points). A maximum score of
11 points can be reached. Data are grouped as nor-
mal bone marrow (NBM), pathological controls (PC)
and MDS, relative distribution of the results for the
score is displayed along the Y-axes. Panel A. repre-
sents the learning cohort consisting of 79 normal
bone marrow samples (NBM), 153 pathological con-
trols (PC) and 119 MDS cases. The FC-erythroid dys-
plasia score could only be calculated in the cases
with data on all four defined parameters (351/670
cases). Panel B. represents the results in the valida-
tion cohort consisting of 42 NBM samples, 106
pathological controls and 93 MDS cases (241/320
cases). Clonal disorders as aplastic anemia and
those within the category of essential thrombo-
cythemia, polycythemia vera and primary myelofi-
brosis were excluded from both cohorts (two and
nine cases for learning and validation cohorts,
respectively). A cut-off of ≥5 points resulted in a
specificity of 90% (95% CI: 84–94%) and a sensitiv-
ity of 33% (95% CI: 24–42) in the learning cohort; in
the validation cohort, specificity was 92% (95% CI:
86–97%) and sensitivity 24% (95% CI: 15–34%).
The numerical score, depicted in panels C and D,
consists of four parameters: increase in CD36 CV
and CD71 CV ; decrease in CD71 MFI; and decrease
or increase of CD117+ erythroid progenitors. A max-
imum score of 4 points can be reached. A cut-off of
≥2 points resulted in a specificity of 90% (95% CI:
84–94%) and a sensitivity of 35% (95% CI: 27–45)
in the learning cohort; in the validation cohort,
specificity and sensitivity were 92% (95% CI: 86–
97%) and 25% (95% CI: 16–35%), respectively. 
Table 4. Results of multivariate logistic regression analysis in learning cohort.
Parameter                                       odds ratio                                                        95% CI                                                      P
rel. CD36 CV                                                   3.7                                                                           1.6 – 8.5                                                             0.003
rel. CD71 CV                                                   3.2                                                                           1.6 – 6.4                                                             0.001
rel. CD71 MFI                                                 2.2                                                                           1.1 – 4.5                                                             0.033
rel. %CD117                                                    1.7                                                                          0.92 – 3.2                                                            0.084
Markers entered in the analysis were relative CD36 MFI, CD36 CV, CD71 MFI and CD71 CV, and the relative percentage of CD117+ erythroid cells (%CD117).  272/535 cases were
available for analysis of which 153 pathological controls and 119 MDS cases in the learning cohort; P<0.001). CI: confidence interval; CV: coefficient of variation;  MFI: mean
fluorescence intensity; P: P-value; rel.: relative.
A B
C D
and then to calculate the weighted FC-erythroid dysplasia
score. This resulted in a specificity of 92% (95% CI: 86–
97%) and a sensitivity of 24% (95% CI: 15–34%) for iden-
tifying MDS-associated erythroid aberrancies by FC
(Figure 3B and Online Supplementary Table S5). In most
cases, the numerical score could have been applied (cut-off
≥2 aberrancies; Figure 3D) with the same result regarding
presence of erythroid dysplasia; only one MDS had
decreased CD71 MFI in combination with an altered
CD117+ percentage.
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Table 5. Reference ranges of FC parameters incorporated in the FC-erythroid dysplasia score (learning cohort).
Reference # of PC # of NBM 
Ranges cases* cases†
relative CV of CD36 <145% 175 92
relative CV of CD71 <133% 177 86
relative MFI of CD71 >46% 250 126
relative %CD117+ erythroid cells 37–212% 182 122
Reference ranges were determined in the learning cohort. Reference ranges represent values relative to median values for the analyzed markers in the erythroid compartment
of normal bone marrow (NBM) subjects (learning cohort). These values represent 10th and/or 90th percentiles as determined in the set of pathological controls (PC) within the
learning cohort. *number of PC cases that were available to calculate cut-off values (10th and 90th percentiles); †number of NBM cases that were available to calculate median
values.  CV: coefficient of variation; MFI: mean fluorescence intensity.
Figure 4. Distribution of erythroid markers analyzed by FC within subgroups of MDS patients and controls within the validation cohort. Results of the analysis of
selected markers of the erythroid lineage in the validation cohort are plotted along the X-axes: relative coefficient of variation (CV) of CD36 and CD71, and relative
percentages of CD117+ erythroid progenitors. Normalization was performed against results for the normal bone marrow (NBM) samples of the validation cohort per
each individual center. Relative frequencies are depicted along the Y-axes. Dotted lines represent results for NBM samples, dashed lines pathological controls (PC),
and solid lines MDS cases. Grey boxes indicate 10th and/or 90th percentiles of pathological controls defined in the learning cohort that were applied for evaluating
aberrancies.
Discussion
Analysis of erythroid dysplasia is rarely included in cur-
rent FC protocols for MDS, since the significance of FC
data from the erythroid lineage is, to a large extent, still
under debate.4 Here, we reported the results of a multicen-
ter study within the IMDSFlow group, which focused on
defining erythroid parameters that enable discrimination
of dyserythropoiesis associated with MDS from non-clon-
al cytopenia. The majority of erythroid FC markers that
are recommended for evaluation of dysplasia according to
ELNet guidelines4 were significantly different between
MDS and controls. Analysis of the presence of aberrancies
in the erythroid markers CD71 and CD36 (expressed as
the CV), together with the MFI of CD71 and an abnormal
percentage of CD117+ erythroid progenitor cells, provided
the best discrimination between MDS and non-clonal
cytopenia. A weighted score based on these four parame-
ters yielded a specificity of 90% (95% CI: 84–94%) in the
learning cohort and 92% (95% CI: 86–97%) in the valida-
tion cohort. Sensitivity of the weighted score was 33%
(95% CI: 24–42%) and 24% (95% CI: 15–34%) in the
learning and validation cohorts, respectively. The latter
lower sensitivity could be explained by a less evidently
increased CD71 CV and decreased CD71 MFI in the MDS
validation cohort compared to the learning cohort. Hence,
fewer MDS cases scored CD71 CV and/or CD71 MFI as
aberrant (Online Supplementary Table S3). Notably, these
scores only reflect the presence of FC-erythroid dysplasia,
not the likelihood of an MDS diagnosis.
Tenth and 90th percentiles in the validation cohort’s con-
trol cases slightly differed from the learning cohort (Online
Supplementary Table S2B). Yet, application of these cut-offs
in the validation cohort resulted in comparable specificity:
91% (95% CI: 84–96%; sensitivity: 27% (95% CI: 18–
37%). In general, cut-off values are most reliable when
defined by standardized analyses of control samples in a
single center. Notably, no consensus has been reached as
to whether percentiles, standard deviations or log differ-
ences should be applied as cut-offs for any of the MDS-
associated aberrancies. 
Specificity of the defined markers for identification of
MDS-associated erythroid changes is considered to be
more important than their general diagnostic value for
T.M. Westers et al.
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Table 6. Results of FC aberrancies in the erythroid lineage and the FC-erythroid dysplasia score among MDS cases and controls within the learn-
ing cohort.
Increased CV Increased CV Decreased De/increased FC-erythroid # of cases
of CD36 of CD71 relative % of CD117+ dysplasia score in flow 
MFI CD71 erythroid ≥5 score*
progenitors
Categories
normal controls 0 5 4 8 3 2/79
pathological controls 10 10 10 19 10 15/153
MDS 30 46 28 34 33 39/119
MDS subcategories
RCUD 25 31 26 41 33 5/15 
RARS(-t) 60 64 33 31 57 8/14
RCMD 28 44 25 32 30 24/79
del(5q) 10 30 38 63 13 1/8
MDS NOS - 80 40 - - -
Pathological control subcategories
iron deficiency anemia 11 0 0 11 6 1/18
anemia in chronic disease† 7 10 3 23 10 3/29
vitamin B12/folic acid deficiencies 0 17 0 25 0 0/6
anemia in auto-immune diseases† 0 0 20 0 0 0/5
anemia due to renal failure 25 0 0 60 - -
anemia other† 0 22 11 0 0 0/5
cytopenia associated with marrow infiltration 0 20 16 40 - -
cytopenia induced by chemotherapy or medication or post-SCT 10 0 24 9 0 0/7
ITP or neutropenia or 17 9 12 9 14 3/21
auto immune cytopenia NOS
reactive conditions or 19 39 24 19 28 5/18
cytopenia induced by infections
normal bone marrow 0 20 33 67 20 1/5
(peripheral cytopenia NOS)
other than defined subcategories NOS 5 0 4 16 0 0/20
inconclusive 0 0 0 18 0 0/11
Displayed numbers correspond to the percentage of cases per subgroup that were beyond the reference ranges (Table 5). The coefficient of variation (CV) for CD71 and CD36
were tested against the 90th percentile; the expression level (mean fluorescence intensity: MFI) of CD71 was against the 10th percentile; and the percentage of CD117 erythroid
progenitor cells was tested against both the 10th and 90th percentiles. Only data of subsets with five or more cases are depicted. Diagonally marked cells represent data not avail-
able or reliable (i.e., missing or only small data sets (<5 cases)) Note: *number of cases with a FC-erythroid dysplasia score of ≥2 per total number of cases in which all param-
eters were available that comprise the score; the subcategories† ”anemia in chronic disease” comprises iron incorporation disorders, bowel diseases, diabetes, etc.,  “anemia in
auto-immune diseases” comprises AIHA, AITP, Rheumatoid Arthritis, SLE, etc. and “anemia other” comprises, among others, cases of normocytic anemia, anemia unexplained;
NOS: not otherwise specified.   
MDS. The specificity may be optimized by increasing the
cut-off from ≥5 to ≥6 points (specificity 96% in both
cohorts), at the cost, however, of a decrease in sensitivity
(24% and 14%, in the learning and validation cohorts,
respectively).
To simplify interpretation of results from erythroid
analysis, a numerical way of counting aberrancies was
tested; a cut-off of ≥2 aberrant markers led to comparable
specificity and sensitivity as for the weighted score.
However, it must be taken into account that the sole com-
bination of CD71 MFI and percentage of CD117+ ery-
throid progenitors is not sufficient to indicate MDS-asso-
ciated changes in the erythroid lineage. Cremers et al.
compared the analysis of the set of four FC-parameters to
erythroid dysplasia as assessed by cytomorphology.29
They demonstrated that FC correlated well with cytomor-
phology, albeit at a lower sensitivity (low/int-1 risk MDS,
64% vs. 84%, respectively); controls showed 11% and
10% of dysplasia by FC and cytomorphology, respective-
ly. The findings presented herein confirmed results from a
recent study28 that reported a significant increase in CD71
CV and CD36 CV to be highly suggestive for MDS. Yet,
discrimination between MDS and controls based on CV
values was less clear in the current dataset. Mathis et al.28
stated that the difference in CD71 CV between MDS and
controls was less pronounced after erythrocyte lysis; how-
ever, this was not the case for CD36 CV. Since all data in
the present study were obtained after erythrocyte lysis, it
might explain the observed differences. It may seem para-
doxical to use erythrocyte lysing procedures when the
focus is on analysis of the erythroid lineage; but lyse-stain-
wash is the recommended protocol for processing samples
for FC in MDS.3 Despite IMDSFlow recommendations,
methodological variation between centers may have led to
differences in results as demonstrated in normal controls.
Harmonization, or even standardization, of methods may
narrow differences and improve validity of conclusions
from multicenter studies, as has been demonstrated with-
in the Euroflow consortium.30 Hence, grouping of data per
technical procedure could have been informative from a
practical perspective; yet, the power of the analyses with-
in and between numerous subgroups of centers would
have been strongly limited by sample sizes. Notably, in
daily practice, FC results in subjects suspected of MDS
should preferably be compared with a center’s own cohort
of control samples. Despite these technical considerations,
our data confirm the robustness of the evaluation of an
increase in CD71 and CD36 CV on erythroid cells.28
Another discriminatory marker was the percentage of
erythroid progenitors defined as CD117+. A potential
marker for future inclusion in erythroid data analysis by
FC is CD105. It has been demonstrated (in normal and
pathological controls) that CD105 is lost before carbonic
anhydrase is expressed, which suggests that the majority
of CD105+ erythroid progenitor cells are not subject to
ammonium chloride-based lysing protocols.16 This con-
firms the robustness of the percentage of erythroid pro-
genitors (CD117+ and/or CD105+) as a marker for ery-
throid dysplasia. Notably, hemodilution impacts the
analysis of the erythroid compartment as it may result in
a lack or paucity of erythroid progenitors, similar to what
is seen in the myelomonocytic compartments. In heavily
hemodiluted samples, the erythroid lineage should be
considered non-evaluable.
Application of CD105 may overcome the potential error
of assigning CD117+ myeloid progenitors as erythroid pro-
genitors, especially when combined with CD117 and an
additional myeloid marker such as CD33. Furthermore,
CD105 overexpression was confirmed in some cases of
MDS in our dataset.18,20 However, we also observed a
decreased expression in MDS. Notably, CD105 expression
was negatively correlated with age in normal controls.
Future studies in larger data sets may elucidate whether
CD105 is truly valuable in analysis of erythroid dysplasia
in MDS.
New insights may improve the impact of FC in the diag-
nosis of MDS. A recent report showed that increased
expression of CD44 on all maturational stages of erythroid
cells was associated with MDS, irrespective of presence or
absence of morphologic dyserythropoiesis.31 In addition,
decreased expression of the major coxsackie-adenovirus
receptor (CAR) was demonstrated in dysplastic CD105+
erythroid progenitors.32,33  The diagnostic value of the here-
in presented parameter combination is limited. Yet, ulti-
mately, the analysis of the erythroid and myelomonocytic
lineages and hematogones should be combined. Further
validation should reveal the power of the herein defined
erythroid markers. Results from a prospective clinical trial
in low/int-1 risk MDS demonstrated that the addition of
proposed erythroid FC-markers to the more widely
acknowledged analysis of the myelomonocytic lineage
increased the sensitivity of MDS-FC from 68 to 80%
(specificity only slightly decreased from 98% to 95%).29 In
addition, it would be relevant to elucidate the value of the
combination of myeloid and erythroid FC markers in
indeterminate cases according to cytomorphology. MDS-
FC of the myelomonocytic lineage has shown to be of
negative predictive value in these cases.34,35 
In view of emerging knowledge from next generation
sequencing analysis, future research may also concern the
analysis of the relation between gene modifications/muta-
tions and FC findings. Data comparing cytogenetic aberra-
tions and FC have already demonstrated distinct pro-
files.36,37 Parallel mutational data in the current cohort are
not available, but it would be of interest to compare, for
instance, the immunophenotypic profile of nucleated ery-
throid cells in relation to the presence of a SF3B1 mutation
since there is a relation between this mutation and the
occurrence of ring sideroblasts.38
Cytomorphology reports dysplastic features in erythro-
poiesis in non-MDS cases, such as reactive conditions.23-25
Moreover, patients with cytopenia due to marrow infiltra-
tion may demonstrate FC aberrancies associated with
MDS. MDS may even coincide with the other malignancy
in these patients.39,40 A subset of patients with reactive
marrows or marrow infiltration in our dataset indeed
showed multiple erythroid aberrancies (5/23 and 2/9,
respectively; Online Supplementary Table S5). Follow-up
analysis after several months may exclude or confirm
MDS in these cases.34,35 This stresses that FC analysis in
suspected MDS, though proven very specific, should
always be part of an integrated diagnostic approach rather
than a solitary diagnostic tool.41 In line with this, FC may
attribute to the diagnostic work-up in cases that show
clonal hematopoiesis of indeterminate potential (CHIP),
particularly when patients present with cytopenia and
have indeterminate cytomorphology and/or non-informa-
tive cytogenetics. 
To summarize, we identified significant aberrancies
with respect to the FC markers recommended by
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IMDSFlow for analysis of the erythroid lineage in MDS.
The best indicators of dysplastic changes associated with
MDS were an increased CV of CD36 and CD71, a
decreased MFI of CD71 in combination with decreased or
increased percentages of erythroid progenitors (CD117+).
Application of the defined marker set demonstrated high
specificity. Future studies should assess the contribution of
the selected erythroid markers to the evaluation of the
myeloid progenitors, the maturing myelomonocytic line-
age, and hematogones in current FC protocols in MDS.
This will be implemented in an upcoming multicenter
data collection exercise within IMDSFlow.
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